Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:
ACNB (ACNB - Free Report) operates as a provider of banking and financial services to individuals and businesses. The Zacks Consensus Estimate for its current year earnings has been revised almost 13.5% downward over the last 60 days.
Amphastar Pharmaceuticals (AMPH - Free Report) is a specialty pharmaceutical company which focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The Zacks Consensus Estimate for its current year earnings has been revised 3.4% downward over the last 60 days.
Entrada Therapeutics (TRDA - Free Report) is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles(TM) to engage intracellular targets. The Zacks Consensus Estimate for its current year earnings has been revised 7.9% downward over the last 60 days.
View the entire Zacks Rank #5 List.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How To Profit From Trillions On Spending For Infrastructure >>
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:
ACNB (ACNB - Free Report) operates as a provider of banking and financial services to individuals and businesses. The Zacks Consensus Estimate for its current year earnings has been revised almost 13.5% downward over the last 60 days.
Amphastar Pharmaceuticals (AMPH - Free Report) is a specialty pharmaceutical company which focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The Zacks Consensus Estimate for its current year earnings has been revised 3.4% downward over the last 60 days.
Entrada Therapeutics (TRDA - Free Report) is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles(TM) to engage intracellular targets. The Zacks Consensus Estimate for its current year earnings has been revised 7.9% downward over the last 60 days.
View the entire Zacks Rank #5 List.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How To Profit From Trillions On Spending For Infrastructure >>
Get the latest research report on AMPH - FREE
Get the latest research report on ACNB - FREE
Get the latest research report on TRDA - FREE